Keyword: PALB2

Study: Cancer patients with certain inherited mutations have cancer outcomes similar to those without inherited mutations

People with an inherited mutation in certain genes, including ATM, CHEK2, PALB2, BRCA or Lynch syndrome genes, have an increased risk of cancer. In this study, researchers wanted to know whether cancer patients with inherited mutations had a different chance of survival than patients without an inherited mutation in these genes. These results showed that, although the risk of cancer is increased, there is no difference in survival after a diagnosis of breast, pancreatic or colorectal cancer with or without these genetic changes. (posted 11/20/25)

Study: Combination treatment for metastatic castration-resistant prostate cancer may be especially effective for people with BRCA1 or BRCA2 mutations

This review summarizes the results of the TALAPRO2 study. It looked at how well the PARP inhibitor Talzenna (talazoparib) works for treating metastatic castration-resistant prostate cancer (mCRPC). Talzenna appears to be most effective for people with BRCA1 or BRCA2 mutations but is also effective for people with certain other mutations. (posted 9/30/25)

Study: Hereditary pancreatic cancer among people of Hispanic ancestry in Mexico

This study looks at people of Mexican ancestry who have pancreatic cancer to identify mutations linked to hereditary cancer. Knowledge of a hereditary cancer mutation can inform patients and their family members about the need for additional surveillance or different treatment options. Access to genetic testing in Mexico is more limited than in the United States. This study emphasizes the importance of genetic testing for inherited cancer risk in pancreatic cancer patients in Mexico. (posted 6/25/25)

Study: Impact of mental healthcare among those with increased pancreatic cancer risk

Pancreatic cancer is often aggressive and diagnosed at a late stage, which can lead to uncertainty and fear. For those at risk due to a genetic mutation or family history, access to surveillance and mental health support is essential to help manage the emotional impact.  (Posted 5/12/25)

Este artículo está disponible en español 

Study: More research points to the benefits of pancreatic cancer screening

People with a family history of pancreatic cancer or those who have an inherited mutation that increases risk may benefit from yearly pancreatic cancer screening. Yearly screening may lead to early diagnosis and longer survival. (Posted 10/8/24)

Este artículo está disponible en español.

Update: A breast cancer vaccine for people with an inherited BRCA1, BRCA2 or PALB2 mutation

A breast cancer vaccine is showing promise in early clinical trials. Initially, the vaccine was tested in people with triple-negative breast cancer (TNBC) who were at high risk for recurrence. Now the vaccine is being tested to lower breast cancer risk among people with an inherited mutation in BRCA1, BRCA2  or PALB2. It is also being tested in people with triple-negative breast cancer who are at high risk for recurrence and are taking the immunotherapy drug Keytruda (pembrolizumab) after completing chemotherapy. (Posted 1/31/24)

Este artículo está disponible en español.

Study: H. pylori bacteria infection and risk of stomach cancer in mutation carriers

The results of a study in Japan show that people with a bacterial infection called H. pylori and an inherited mutation in an ATM, BRCA1, BRCA2 or PALB2 gene have a high risk of stomach cancer.   (Posted 1/19/24)

Este artículo está disponible en español.

Study: Benefit of pancreatic cancer screening

Among people with an inherited mutation in a BRCA1 or BRCA2 gene, screening for pancreatic cancer found most cancers at an earlier stage when they could be treated by surgery. Posted 1/17/24)

Este artículo está disponible en español.

Update: New first-line treatment option for metastatic prostate cancer

The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)

Este artículo está disponible en español.

Study: Promising early results for treating metastatic prostate cancer

The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)

Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage. 

Este artículo está disponible en español.